Search results for "Infarction"

showing 10 items of 1208 documents

Randomised comparison of zofenopril and ramipril plus acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfu…

2015

Objective Conflicting evidence exists on the benefits of treating patients with coronary artery disease and preserved left ventricular ejection fraction (LVEF) with an ACE inhibitor. This retrospective analysis of the SMILE-4 Study sought to compare the efficacy of zofenopril 60 mg plus acetylsalicylic acid (ASA) versus ramipril 10 mg plus ASA 100 mg in patients with acute myocardial infarction (AMI) and heart failure, according to an impaired or preserved LVEF. Methods The primary study end point was 1-year combined occurrence of death or hospitalisation for cardiovascular causes. A preserved LVEF was defined by a baseline LVEF >40% and an impaired one by an LVEF ≤40%. Results 448 patients…

Ramiprilmedicine.medical_specialtyacute myocardial infarctionInfarctionramiprilCoronary Artery DiseaseCoronary artery diseasechemistry.chemical_compoundInternal medicinemedicinezofenopril1506cardiovascular diseasesMyocardial infarctionleft ventricular dysfunctionEjection fractionbusiness.industryleft ventricular ejection fractionmedicine.diseaseZofenoprilangiotensin-converting enzyme inhibitorsangiotensin-converting enzyme inhibitorchemistryacute myocardial infarction; angiotensin-converting enzyme inhibitors; left ventricular dysfunction; left ventricular ejection fractionHeart failureACE inhibitorcardiovascular systemCardiologyCardiology and Cardiovascular Medicinebusinesscirculatory and respiratory physiologyBiomedical engineeringmedicine.drugOpen Heart
researchProduct

Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials

2017

Summary Background Studies have challenged the appropriateness of accepted blood pressure targets. We hypothesised that different levels of low blood pressure are associated with benefit for some, but harm for other outcomes. Methods In this analysis, we assessed the previously reported outcome data from high-risk patients aged 55 years or older with a history of cardiovascular disease, 70% of whom had hypertension, from the ONTARGET and TRANSCEND trials investigating ramipril, telmisartan, and their combination, with a median follow-up of 56 months. Detailed descriptions of randomisation and intervention have already been reported. We analysed the associations between mean blood pressure a…

Ramiprilmedicine.medical_specialtybusiness.industryMedicine (all)General Medicine030204 cardiovascular system & hematologymedicine.diseasePrehypertensionSurgery03 medical and health sciences0302 clinical medicineBlood pressureMean blood pressureHeart failureInternal medicinemedicineCardiology030212 general & internal medicineMyocardial infarctionTelmisartanbusinessStrokemedicine.drug
researchProduct

Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk

2019

Abstract Aims Studies have shown a non-linear relationship between systolic blood pressure (SBP) and diastolic blood pressure (DBP) and outcomes, with increased risk observed at both low and high blood pressure (BP) levels. We hypothesized that the BP-risk association is different in individuals with and without diabetes at high cardiovascular risk. Methods and results We identified patients with (N = 11 487) or without diabetes (N = 19 450), from 30 937 patients, from 133 centres in 44 countries with a median follow-up of 56 months in the ONTARGET/TRANSCEND studies. Patients had a prior history of stroke, myocardial infarction (MI), peripheral artery disease, or were high-risk diabetics. P…

Ramiprilmedicine.medical_specialtyhypertensionSystoleAngiotensin-Converting Enzyme Inhibitors030204 cardiovascular system & hematologyPeripheral Arterial Disease03 medical and health sciences0302 clinical medicineRamiprilDiastoleRisk FactorsInternal medicineDiabetes mellitusDiabetes MellitusmedicineHumanshigh cardiovascular riskTelmisartan030212 general & internal medicineMyocardial infarctionStrokeRetrospective StudiesHeart Failurediabetesbusiness.industryHazard ratioblood pressureBlood Pressure Determinationmedicine.diseasestrokeHospitalizationmyocardial infarctionBlood pressureCardiovascular DiseasesCase-Control StudiesHeart failureCardiologyDrug Therapy CombinationTelmisartanCardiology and Cardiovascular MedicinebusinessAngiotensin II Type 1 Receptor Blockersmedicine.drugEuropean Heart Journal
researchProduct

Opposite Role of Pro-Inflammatory Alleles in Acute Myocardial Infarction and Longevity: Results of Studies Performed in a Sicilian Population

2006

The major trait characterizing offspring in centenarians is a reduction in the prevalence of cardiovascular disease. Because a pro-inflammatory genotype seems to contribute significantly to the risk of coronary heart disease, alleles associated with disease susceptibility would not be included in the genetic background favoring longevity, as suggested by our previous studies on inflammatory cytokines. To confirm whether genotypes of inflammatory molecules play an opposite role in atherosclerosis and longevity, we are studying the role of other proinflammatory alleles, such as pyrin and CCR5, in acute myocardial infarction and longevity. The results support the hypothesis that the genetic ba…

Receptors CCR5media_common.quotation_subjectPopulationMyocardial InfarctionDiseasePyrin domainGeneral Biochemistry Genetics and Molecular BiologyProinflammatory cytokineAMIlongevityHistory and Philosophy of SciencepyrinGenotypeHumansMedicineGenetic Predisposition to DiseaseAlleleeducationSicilyAllelesmedia_commonAged 80 and overeducation.field_of_studybusiness.industryGeneral NeuroscienceLongevityCytoskeletal ProteinsinflammationAcute DiseaseImmunologyCentenarianbusinessCCR5Annals of the New York Academy of Sciences
researchProduct

C-X-C Motif Chemokine Receptor 4 Blockade Promotes Tissue Repair After Myocardial Infarction by Enhancing Regulatory T Cell Mobilization and Immune-R…

2019

Background: Acute myocardial infarction (MI) elicits an inflammatory response that drives tissue repair and adverse cardiac remodeling. Inflammatory cell trafficking after MI is controlled by C-X-C motif chemokine ligand 12 (CXCL12) and its receptor, C-X-C motif chemokine receptor 4 (CXCR4). CXCR4 antagonists mobilize inflammatory cells and promote infarct repair, but the cellular mechanisms are unclear. Methods: We investigated the therapeutic potential and mode of action of the peptidic macrocycle CXCR4 antagonist POL5551 in mice with reperfused MI. We applied cell depletion and adoptive transfer strategies using lymphocyte-deficient Rag1 knockout mice; DEREG mice, which express a diphth…

Receptors CXCR4Regulatory T cellCXCR4 antagonistSus scrofaAnti-Inflammatory AgentsMyocardial InfarctionNeovascularization PhysiologicMice TransgenicInflammation030204 cardiovascular system & hematologyT-Lymphocytes RegulatoryVentricular Function Left03 medical and health sciencesChemokine receptor0302 clinical medicineImmune systemPhysiology (medical)medicineAnimalsMyocardial infarction030304 developmental biology0303 health sciencesMobilizationVentricular Remodelingbusiness.industryMyocardiumProteinsDendritic CellsRecovery of FunctionRegulatory T cellsTissue repairmedicine.diseaseMyocardial ContractionBlockadeMice Inbred C57BLDisease Models Animalmedicine.anatomical_structureCancer researchmedicine.symptomCardiology and Cardiovascular MedicinebusinessSignal TransductionCirculation
researchProduct

Mechanisms and predictors of chronic facial pain in lateral medullary infarction

2001

The purpose of this study was to identify clinical predictors and anatomical structures involved in patients with pain after dorsolateral medullary infarction. Eight out of 12 patients (67%) developed poststroke pain within 12 days to 24 months after infarction. The pain occurred in the ipsilateral face (6 patients) and/or the contralateral limbs and trunk (5 patients, 3 of whom also had facial pain). Ipsilateral facial pain was significantly correlated with lower medullary lesions, including those of the spinal trigeminal tract and/or nucleus, as documented by magnetic resonance imaging. The R2 blink reflex component was abnormal only in patients with facial pain. Likewise, pain and temper…

Referred painmedicine.diagnostic_testMedullary cavitybusiness.industrySpinal trigeminal nucleusInfarctionMagnetic resonance imagingmedicine.diseaseCentral nervous system diseasemedicine.anatomical_structureNeurologyAnesthesiamedicineMedulla oblongataNeurology (clinical)Corneal reflexbusinessAnnals of Neurology
researchProduct

Frequency of Left Ventricular Hypertrophy in Non-Valvular Atrial Fibrillation

2015

Left ventricular hypertrophy (LVH) is significantly related to adverse clinical outcomes in patients at high risk of cardiovascular events. In patients with atrial fibrillation (AF), data on LVH, that is, prevalence and determinants, are inconsistent mainly because of different definitions and heterogeneity of study populations. We determined echocardiographic-based LVH prevalence and clinical factors independently associated with its development in a prospective cohort of patients with non-valvular (NV) AF. From the "Atrial Fibrillation Registry for Ankle-brachial Index Prevalence Assessment: Collaborative Italian Study" (ARAPACIS) population, 1,184 patients with NVAF (mean age 72 ± 11 yea…

RegistrieMaleCross-sectional studyMyocardial InfarctionLongitudinal StudieLeft ventricular hypertrophyCohort Studiesnon-valvular atrial fibrillationAtrial Fibrillation80 and overPrevalenceechocardiographyMyocardial infarctionLongitudinal StudiesProspective StudiesRegistriesProspective cohort studyUltrasonographyAged 80 and overeducation.field_of_studyMedicine (all)Atrial fibrillationDiabetes MellituMiddle AgedLeft Ventricularleft ventricular hypertrophyItalyHypertensionCardiologyAge Distribution; Aged; Aged 80 and over; Ankle Brachial Index; Atrial Fibrillation; Cohort Studies; Cross-Sectional Studies; Diabetes Mellitus; Female; Humans; Hypertension; Hypertrophy Left Ventricular; Italy; Logistic Models; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Prevalence; Prospective Studies; Ultrasonography; Registries; Cardiology and Cardiovascular Medicine; Medicine (all)Hypertrophy Left VentricularFemaleCardiology and Cardiovascular MedicineHumanmedicine.medical_specialtyLogistic ModelPopulationConcentric hypertrophySocio-culturalenon-valvular atrial fibrillation left ventricular hypertrophy echocardiography cardiovascular diseasesPeripheral Arterial DiseaseAge DistributionInternal medicinemedicineDiabetes MellitusHumansAnkle Brachial Indexcardiovascular diseaseseducationAgedCross-Sectional Studiebusiness.industryAge Distribution; Aged; Aged 80 and over; Ankle Brachial Index; Atrial Fibrillation; Cohort Studies; Cross-Sectional Studies; Diabetes Mellitus; Female; Humans; Hypertension; Hypertrophy Left Ventricular; Italy; Logistic Models; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Prevalence; Prospective Studies; Ultrasonography; Registries; Cardiology and Cardiovascular MedicineOdds ratioHypertrophymedicine.diseasecardiovascular diseasesProspective StudieCross-Sectional StudiesLogistic ModelsCohort StudiebusinessAge Distribution; Aged; Aged 80 and over; Ankle Brachial Index; Atrial Fibrillation; Cohort Studies; Cross-Sectional Studies; Diabetes Mellitus; Female; Humans; Hypertension; Hypertrophy Left Ventricular; Italy; Logistic Models; Longitudinal Studies; Male; Middle Aged; Myocardial Infarction; Peripheral Arterial Disease; Prevalence; Prospective Studies; Ultrasonography; Registries
researchProduct

COVID-19 pandemic, mechanical reperfusion and 30-day mortality in ST elevation myocardial infarction

2022

ObjectiveThe initial data of the International Study on Acute Coronary Syndromes - ST Elevation Myocardial Infarction COVID-19 showed in Europe a remarkable reduction in primary percutaneous coronary intervention procedures and higher in-hospital mortality during the initial phase of the pandemic as compared with the prepandemic period. The aim of the current study was to provide the final results of the registry, subsequently extended outside Europe with a larger inclusion period (up to June 2020) and longer follow-up (up to 30 days).MethodsThis is a retrospective multicentre registry in 109 high-volume primary percutaneous coronary intervention (PPCI) centres from Europe, Latin America, S…

RegistrieMaleST Elevation Myocardial Infarction/diagnosisTime FactorsPercutaneousmedicine.medical_treatmentVascular damage Radboud Institute for Health Sciences [Radboudumc 16]Coronary Artery DiseasePractice Patterns030204 cardiovascular system & hematologyRate ratioTime-to-Treatment/trendsCardiologists0302 clinical medicineRetrospective StudieHeart RateRisk FactorsPandemicST segmentRegistriesHospital Mortality030212 general & internal medicineMyocardial infarctionPractice Patterns Physicians'10. No inequalityPercutaneous Coronary Intervention/adverse effectsHospital Mortality/trendsCOVID-19; myocardial infarction; percutaneous coronary interventionIncidenceIncidence (epidemiology)*percutaneous coronary interventionMiddle Aged3. Good healthTreatment Outcomemyocardial infarctionCardiologyFemale*COVID-19Cardiology and Cardiovascular MedicineCardiologists/trendsHumanCOVID-19; myocardial infarction; percutaneous coronary intervention; Aged; Cardiologists; Female; Hospital Mortality; Humans; Incidence; Male; Middle Aged; Percutaneous Coronary Intervention; Practice Patterns Physicians'; Registries; Retrospective Studies; Risk Assessment; Risk Factors; ST Elevation Myocardial Infarction; Time Factors; Time-to-Treatment; Treatment Outcome; COVID-19medicine.medical_specialtyTime FactorCoronavirus disease 2019 (COVID-19)CardiologistRisk AssessmentTime-to-Treatment03 medical and health sciencesInternal medicinemedicineHumansAcute Coronary SyndromePandemicsRetrospective StudiesAgedPhysicians'SARS-CoV-2business.industryRisk FactorCOVID-19 myocardial infarction percutaneous coronary interventionpercutaneous coronary interventionPercutaneous coronary interventionCOVID-19*myocardial infarctionmedicine.diseasePractice Patterns Physicians'/trendsST Elevation Myocardial Infarctionbusiness
researchProduct

Moderne Therapie bei akutem Koronarsyndrom

2002

Inhibition of platelet aggregation with aspirin and anticoagulation with unfractionated heparin can be considered the gold standard treatment of patients with acute coronary syndromes. Replacement of unfractionated heparins by low-molecular weight heparins seem to further improve the cardiovascular risk. Additional treatment with glycoprotein IIb/IIIa receptor blockers led to a further reduction of the clinical event rate, especially in patients undergoing coronary interventions during an acute coronary syndrome (more than 30% relative risk reduction). However, the latter substances did only lead to marginal improvements in the setting of a conservative stabilization of patients with acute …

Relative risk reductionAcute coronary syndromeAspirinmedicine.medical_specialtybusiness.industryUnstable anginaGeneral Medicinemedicine.diseaseClopidogrelCoronary artery diseaseAnginaInternal medicineCardiologyMedicineMyocardial infarctionbusinessmedicine.drugMedizinische Klinik
researchProduct

Prognostic differences between routine invasive and conservative strategies for the management of high-risk, non-ST segment acute coronary syndromes:…

2007

Abstract Background The optimal revascularization strategy for non-ST elevation acute coronary syndromes (NSTE-ACS) remains controversial, especially in a real world context. The objective of this work was to assess differences at 1 year in all-cause mortality and the composite endpoint of mortality or acute myocardial infarction (MI) between two management strategies for NSTE-ACS: a conservative strategy (CS) versus a routine invasive strategy (RIS). Methods Of 799 consecutive patients admitted to our institution, 369 were treated with CS (from January 2001 to October 2002); 430 patients admitted with the same diagnosis were treated with RIS (from November 2002 to November 2004). A propens…

Relative risk reductionmedicine.medical_specialtyeducation.field_of_studybusiness.industrymedicine.medical_treatmentMortality ratePopulationContext (language use)Revascularizationmedicine.diseaseLower riskMedication prescriptionSurgeryInternal medicineInternal MedicinemedicineMyocardial infarctionbusinesseducationEuropean Journal of Internal Medicine
researchProduct